MARY FINK, AHCNS
Neuroscience Clinical Nurse Specialist in SAINT LOUIS, Missouri. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
MARY FINK, AHCNS reported a CMS MIPS final score of 79.292/100 — below the 83.1 national average — and filed 486 Medicare Part D claims in 2023.
- 79.292/100
- MIPS score · -4 vs avg
- 486
- Part D claims, 2023
- $117.58
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
MARY FINK, AHCNS's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
79 30th percentile higher than 30% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
What does the federal data show about MARY FINK, AHCNS?
Near national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Missouri
How Neuroscience Clinical Nurse Specialist compares to other specialties among Missouri providers
Neuroscience Clinical Nurse Specialist share within Missouri
Neuroscience Clinical Nurse Specialist is one of the more visible NUCC categories in Missouri
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
MARY FINK, AHCNS's 2023 MIPS final score plotted against the Neuroscience Clinical Nurse Specialist national average
- MIPS Final Score
- 79.292/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Neuroscience Clinical Nurse Specialist) — 79.292/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Neuroscience Clinical Nurse Specialist US NPIs
79.292/100 MIPS final score — 3.8 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Neuroscience Clinical Nurse Specialist. Quality dim: 71.46. Cost dim: 59.5132.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MARY FINK, AHCNS appears in the CMS NPPES registry as a Neuroscience Clinical Nurse Specialist provider holding AHCNS credentials at 4921 PARKVIEW PL, SAINT LOUIS, MO, 63110, with a listed phone of (314) 362-3293. NPI 1659461606 was issued on 10/13/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what FINK most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 486 prescription claims written by this provider, covering 113 Medicare beneficiaries and totaling roughly $869K in drug spend. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 79.292/100 for the 2023 performance year (Quality 71.46, Cost 59.5132), compared with the national average of 83.1.
Neuroscience Clinical Nurse Specialist is a narrow specialty nationwide, with 54 enrolled providers across 23 states and an average of 591 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1659461606 |
|---|---|
| Specialty | Neuroscience Clinical Nurse Specialist |
| Credentials | AHCNS |
| Gender | Female |
| NPI Issued | 10/13/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MARY FINK, AHCNS's current license status, disciplinary history, and board certifications with the Missouri Board of Registration for the Healing Arts in Missouri before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where MARY FINK, AHCNS bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARY FINK, AHCNS. Source: openpaymentsdata.cms.gov.
Total received
$118
Largest payer
Alexion Pharmaceuticals, Inc.
Most common payment type
Education
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 676
- Total Day Supply
- 19,333
- Generic Drug Cost
- $127K
Patient Demographics
- Average Patient Age
- 59.0 years
- Avg HCC Risk Score
- 1.83
- Gender Split
- 81% female / 19% male
- Age Distribution
- <65: 70, 65-74: 34, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What MARY FINK, AHCNS prescribes most
Top Medicare Part D drugs by claim count, 2023
- Baclofen
Baclofen
50 claims
- Dimethyl Fumarate
Dimethyl Fumarate
34 claims
- Gabapentin
Gabapentin
30 claims
- Kesimpta Pen
Kesimpta Pen
29 claims
- Amitriptyline Hcl
Amitriptyline Hcl
26 claims
- Tizanidine Hcl
Tizanidine Hcl
25 claims
- Bupropion Xl 16
Bupropion Xl
16 claims
- Oxybutynin Chlorid… 16
Oxybutynin Chloride Er
16 claims
| Drug | Claims |
|---|---|
| Baclofen | 50 |
| Dimethyl Fumarate | 34 |
| Gabapentin | 30 |
| Kesimpta Pen Ofatumumab | 29 |
| Amitriptyline Hcl | 26 |
| Tizanidine Hcl | 25 |
| Bupropion Xl Bupropion Hcl | 16 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 16 |
| Duloxetine Hcl | 15 |
| Methotrexate Methotrexate Sodium | 14 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Neuroscience Clinical Nurse Specialist Overview
How MARY FINK, AHCNS fits within the Neuroscience Clinical Nurse Specialist landscape nationally.
MARY FINK, AHCNS's 486 claims are below the specialty average of 591.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Missouri
Frequently Asked Questions
What is MARY FINK, AHCNS's specialty? ▼
How much does MARY FINK, AHCNS prescribe under Medicare Part D? ▼
What is MARY FINK, AHCNS's Medicare quality score? ▼
Where is MARY FINK, AHCNS located? ▼
What is MARY FINK, AHCNS's NPI number? ▼
How many Neuroscience Clinical Nurse Specialist providers are there in the US? ▼
What drugs does MARY FINK, AHCNS prescribe most often? ▼
Does MARY FINK, AHCNS accept Medicare? ▼
How can I verify MARY FINK, AHCNS's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology